Sanofi (SNY)
(Delayed Data from NSDQ)
$46.75 USD
+1.11 (2.43%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $46.00 -0.75 (-1.60%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth C Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Sanofi has a PEG ratio of 1.15 compared to the Large Cap Pharmaceuticals industry's PEG ratio of 1.24.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SNY 46.75 +1.11(2.43%)
Will SNY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SNY
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down
SNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
AZN Q2 Earnings Meet Estimates, Sales Beat as Key Drugs Outperform
RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now?
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
Other News for SNY
Notable healthcare headlines for the week: Trump’s ultimatum to big pharma, Novo Nordisk, UnitedHealth and Moderna in focus
Top global stories this week: HSBC, AstraZeneca, Nissan among notable names
Market Voices: Trump vs. Big Pharma, Swiss tariffs, tariff legality
Putnam U.S. Large Cap Value Equity Concentrated SMA Q2 2025 Commentary
Experts helping vaccine advisors are reportedly ousted at CDC